#IDWeek 2016

With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.

In an ongoing small trial, adding a biweekly infusion of ibalizumab has helped quite a few people on failing antiretroviral regimens.

HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.

Taking omega-3 fatty acid supplements may lower triglycerides and inflammation.

An analysis of a large patient database found that a computer algorithm could identify those at high risk for HIV.

In a 111-person group of people treated for HIV, the average viral reservoir half-life was 12 years.

It’s unclear, however, whether going on Truvada as pre-exposure prophylaxis led men who have sex with men to contract more STIs.

In a Phase III trial, participants responded well to the addition of biweekly injections of the cloned antibody ibalizumab.

Just 11 percent got anal pap smears in a recent study.